Skip to main content
Erschienen in: Abdominal Radiology 8/2019

30.04.2019 | Hepatobiliary

Assessment of liver fibrosis with gadoxetic acid-enhanced MRI: comparisons with transient elastography, ElastPQ, and serologic fibrosis markers

verfasst von: Hyeon Ji Jang, Ji Hye Min, Jeong Eun Lee, Kyung Sook Shin, Kyung-Hee Kim, Seo-Youn Choi

Erschienen in: Abdominal Radiology | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To compare the diagnostic performance of gadoxetic acid-enhanced magnetic resonance imaging (MRI), ultrasonography (US)—based elastography, and serologic fibrosis markers in assessing the stage of liver fibrosis.

Materials and methods

This retrospective study included 67 patients (55 male and 12 female; mean age 62.5 years) who underwent gadoxetic acid-enhanced MRI and liver stiffness measurements before liver biopsy or surgery between January 2014 and January 2018. Measurements were performed using transient elastography (TE), ultrasound shear wave elastography point quantification (ElastPQ), and blood tests. The following MRI-based fibrosis markers were assessed: contrast enhancement index (CEI), liver–spleen contrast ratio (LSC), liver–portal vein contrast ratio (LPC), and signal intensity ratio (SIR). The diagnostic performances of fibrosis markers were compared using the area under the receiver operating characteristic curve (AUC), with histopathologic fibrosis stage as the reference standard.

Results

The fibrosis stages were F0–F1 (n = 17), F2 (n = 7), F3 (n = 20), and F4 (n = 23). MRI-based fibrosis markers negatively correlated with histologic stage: CEI (r = –0.786); LSC (r = − 0.718); LPC (r = − 0.448); and SIR (r = − 0.617; all P < 0.001). For diagnosis of either significant liver fibrosis (≥ F2) or cirrhosis (F4), the CEI provided better diagnostic accuracy (AUC = 0.898 and 0.881) than the aspartate aminotransferase-to-platelet ratio index (APRI) (AUC = 0.699 and 0.715; all P < 0.05). The CEI displayed similar diagnostic accuracy for ≥ F2 or F4 when using TE (AUC = 0.866 and 0.884, both P > 0.05) or ElastPQ [AUC = 0.751 (P = 0.021) and AUC = 0.786 (P = 0.234)].

Conclusions

The CEI measured by gadoxetic acid-enhanced MRI allows the staging of liver fibrosis, with a diagnostic accuracy comparable to that of TE and superior to that of ElastPQ or APRI.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M (1999) Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131:174-181CrossRefPubMed Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M (1999) Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131:174-181CrossRefPubMed
6.
Zurück zum Zitat Horowitz JM, Venkatesh SK, Ehman RL, Jhaveri K, Kamath P, Ohliger MA, Samir AE, Silva AC, Taouli B, Torbenson MS, Wells ML, Yeh B, Miller FH (2017) Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel. Abdom Radiol (NY) 42:2037-2053. https://doi.org/10.1007/s00261-017-1211-7 CrossRef Horowitz JM, Venkatesh SK, Ehman RL, Jhaveri K, Kamath P, Ohliger MA, Samir AE, Silva AC, Taouli B, Torbenson MS, Wells ML, Yeh B, Miller FH (2017) Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel. Abdom Radiol (NY) 42:2037-2053. https://​doi.​org/​10.​1007/​s00261-017-1211-7 CrossRef
7.
Zurück zum Zitat Singh S, Venkatesh SK, Wang Z, Miller FH, Motosugi U, Low RN, Hassanein T, Asbach P, Godfrey EM, Yin M, Chen J, Keaveny AP, Bridges M, Bohte A, Murad MH, Lomas DJ, Talwalkar JA, Ehman RL (2015) Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol 13:440-451.e446. https://doi.org/10.1016/j.cgh.2014.09.046 CrossRefPubMed Singh S, Venkatesh SK, Wang Z, Miller FH, Motosugi U, Low RN, Hassanein T, Asbach P, Godfrey EM, Yin M, Chen J, Keaveny AP, Bridges M, Bohte A, Murad MH, Lomas DJ, Talwalkar JA, Ehman RL (2015) Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol 13:440-451.e446. https://​doi.​org/​10.​1016/​j.​cgh.​2014.​09.​046 CrossRefPubMed
13.
Zurück zum Zitat Kobayashi S, Matsui O, Gabata T, Koda W, Minami T, Ryu Y, Kozaka K, Kitao A (2012) Relationship between signal intensity on hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging and prognosis of borderline lesions of hepatocellular carcinoma. Eur J Radiol 81:3002-3009. https://doi.org/10.1016/j.ejrad.2012.03.029 CrossRefPubMed Kobayashi S, Matsui O, Gabata T, Koda W, Minami T, Ryu Y, Kozaka K, Kitao A (2012) Relationship between signal intensity on hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging and prognosis of borderline lesions of hepatocellular carcinoma. Eur J Radiol 81:3002-3009. https://​doi.​org/​10.​1016/​j.​ejrad.​2012.​03.​029 CrossRefPubMed
18.
Zurück zum Zitat Nishie A, Asayama Y, Ishigami K, Tajima T, Kakihara D, Nakayama T, Takayama Y, Okamoto D, Taketomi A, Shirabe K, Fujita N, Obara M, Yoshimitsu K, Honda H (2012) MR prediction of liver fibrosis using a liver-specific contrast agent: Superparamagnetic iron oxide versus Gd-EOB-DTPA. J Magn Reson Imaging 36:664-671. https://doi.org/10.1002/jmri.23691 CrossRefPubMed Nishie A, Asayama Y, Ishigami K, Tajima T, Kakihara D, Nakayama T, Takayama Y, Okamoto D, Taketomi A, Shirabe K, Fujita N, Obara M, Yoshimitsu K, Honda H (2012) MR prediction of liver fibrosis using a liver-specific contrast agent: Superparamagnetic iron oxide versus Gd-EOB-DTPA. J Magn Reson Imaging 36:664-671. https://​doi.​org/​10.​1002/​jmri.​23691 CrossRefPubMed
21.
Zurück zum Zitat Goshima S, Kanematsu M, Watanabe H, Kondo H, Kawada H, Moriyama N, Bae KT (2012) Gd-EOB-DTPA-enhanced MR imaging: prediction of hepatic fibrosis stages using liver contrast enhancement index and liver-to-spleen volumetric ratio. J Magn Reson Imaging 36:1148-1153. https://doi.org/10.1002/jmri.23758 CrossRefPubMed Goshima S, Kanematsu M, Watanabe H, Kondo H, Kawada H, Moriyama N, Bae KT (2012) Gd-EOB-DTPA-enhanced MR imaging: prediction of hepatic fibrosis stages using liver contrast enhancement index and liver-to-spleen volumetric ratio. J Magn Reson Imaging 36:1148-1153. https://​doi.​org/​10.​1002/​jmri.​23758 CrossRefPubMed
25.
Zurück zum Zitat Motosugi U, Ichikawa T, Sou H, Sano K, Tominaga L, Kitamura T, Araki T (2009) Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 30:1042-1046. https://doi.org/10.1002/jmri.21956 CrossRefPubMed Motosugi U, Ichikawa T, Sou H, Sano K, Tominaga L, Kitamura T, Araki T (2009) Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 30:1042-1046. https://​doi.​org/​10.​1002/​jmri.​21956 CrossRefPubMed
27.
Zurück zum Zitat Group FMCS (1994) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 20:15-20CrossRef Group FMCS (1994) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 20:15-20CrossRef
34.
Zurück zum Zitat Tsuboyama T, Onishi H, Kim T, Akita H, Hori M, Tatsumi M, Nakamoto A, Nagano H, Matsuura N, Wakasa K, Tomoda K (2010) Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 255:824-833. https://doi.org/10.1148/radiol.10091557 CrossRefPubMed Tsuboyama T, Onishi H, Kim T, Akita H, Hori M, Tatsumi M, Nakamoto A, Nagano H, Matsuura N, Wakasa K, Tomoda K (2010) Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 255:824-833. https://​doi.​org/​10.​1148/​radiol.​10091557 CrossRefPubMed
36.
Zurück zum Zitat van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE (1999) Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther 290:153-157PubMed van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE (1999) Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther 290:153-157PubMed
37.
Zurück zum Zitat Weinmann HJ, Bauer H, Frenzel T, Muhler A, Ebert W (1996) Mechanism of hepatic uptake of gadoxetate disodium. Acad Radiol 3 Suppl 2:S232-234CrossRefPubMed Weinmann HJ, Bauer H, Frenzel T, Muhler A, Ebert W (1996) Mechanism of hepatic uptake of gadoxetate disodium. Acad Radiol 3 Suppl 2:S232-234CrossRefPubMed
40.
Zurück zum Zitat Kim T, Murakami T, Hasuike Y, Gotoh M, Kato N, Takahashi M, Miyazawa T, Narumi Y, Monden M, Nakamura H (1997) Experimental hepatic dysfunction: evaluation by MRI with Gd-EOB-DTPA. J Magn Reson Imaging 7:683-688CrossRefPubMed Kim T, Murakami T, Hasuike Y, Gotoh M, Kato N, Takahashi M, Miyazawa T, Narumi Y, Monden M, Nakamura H (1997) Experimental hepatic dysfunction: evaluation by MRI with Gd-EOB-DTPA. J Magn Reson Imaging 7:683-688CrossRefPubMed
47.
Zurück zum Zitat Yilmaz Y, Yonal O, Kurt R, Bayrak M, Aktas B, Ozdogan O (2011) Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease. Hepat Mon 11:103-106PubMedPubMedCentral Yilmaz Y, Yonal O, Kurt R, Bayrak M, Aktas B, Ozdogan O (2011) Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease. Hepat Mon 11:103-106PubMedPubMedCentral
Metadaten
Titel
Assessment of liver fibrosis with gadoxetic acid-enhanced MRI: comparisons with transient elastography, ElastPQ, and serologic fibrosis markers
verfasst von
Hyeon Ji Jang
Ji Hye Min
Jeong Eun Lee
Kyung Sook Shin
Kyung-Hee Kim
Seo-Youn Choi
Publikationsdatum
30.04.2019
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 8/2019
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-019-02041-z

Weitere Artikel der Ausgabe 8/2019

Abdominal Radiology 8/2019 Zur Ausgabe

Classics in Abdominal Radiology

A “dumbbell” vesicourethral stone

Classics in Abdominal Radiology

The “tangential calcium” sign

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.